Brain Tumour Targeting Team Awarded Additional Funding
TORONTO, ONTARIO--(Marketwired - April 22, 2013) - Arch Biopartners Inc ("Arch" or the "Company")(CNSX:ACH)(OTCBB:FOIFF) today announced Dr. Stephen Robbins and his co-collaborators have been awarded $750,000 from Alberta Innovates' Collaborative Research and Innovation Opportunities ("CRIO") Cancer Project to support his team's ongoing work in developing new diagnostic and therapeutic treatments for malignant brain tumours.
Arch Scientists Publish Data Linking Inflammatory Enzymes to Inflammatory Bowel Disease
TORONTO, ONTARIO--(Marketwired - April 3, 2013) - Arch Biopartners Inc ("Arch" or the "Company") (CNSX:ACH)(OTCBB:FOIFF) today announced that Arch scientists have co-authored a paper disclosing findings that links inflammatory bowel disease ("IBD") to caspase 1, a key enzyme that regulates inflammation and cell homeostasis in the gut.
Arch Biopartners Announces Shareholder Approval to Allow Listing to Move to New Exchange
TORONTO, ONTARIO--(Marketwire - April 1, 2013) - Arch Biopartners Inc. ("Arch" or the "Company") (CNSX:ACH)(OTCBB:FOIFF) today announced that the Company received approval from shareholders to approve all resolutions that were put forth at its Annual Meeting of Shareholders held on March 29, 2013 in Toronto (the "Meeting") and as disclosed in its management information circular filed on SEDAR in connection to the Meeting.